How Long Does Botox Last? Duration by Product and Area

Botox Cosmetic lasts approximately 3 to 4 months in the frown lines between the brows. That is not a clinic estimate or an industry rule of thumb. It is the sentence printed in the FDA approved prescribing information, and it is the only duration claim the manufacturer is permitted to make for that area.

The trial data underneath that sentence is more useful than the sentence itself. In the two pivotal glabellar line studies, investigators rated 74 percent of treated subjects as having none or mild severity at day 7, 80 percent at day 30, 70 percent at day 60, 48 percent at day 90, and 25 percent at day 120. Subjects rating their own change reported higher numbers at every point, ending at 39 percent still improved at day 120.

Read those figures as a curve, not a countdown. Roughly half of treated people had lost the labeled result by the three month mark, a quarter still had it at four months, and the population moved from one state to the other gradually. This is why some patients say their Botox lasts four months and others in the same practice say ten weeks, and why both can be describing an ordinary outcome.

The label also sets a floor on retreatment. It states that the safety and effectiveness of dosing more frequently than every 3 months has not been clinically evaluated, and every other approved neurotoxin carries a version of the same instruction. That is a separate question from how long your result lasts, and we cover the cadence decision in the retreatment guide.

Botox starts working within a day or two and reaches a result worth assessing around two weeks. The Botox Cosmetic label describes it plainly: the initial doses induce chemical denervation of the injected muscles one to two days after injection, increasing in intensity during the first week. The American Academy of Dermatology tells patients most people see results within 3 to 7 days.

The practical consequence is that the first half of week one tells you almost nothing. Movement is still present, the softening is partial, and the areas that respond fastest are not always the ones you care about. People who panic on day three and people who declare victory on day three are making the same mistake.

Products differ slightly at the front end. The Xeomin label states that the median onset of effect occurs within two to seven days after injection. That is the same broad window, described with a different statistic.

Because onset and duration are measured from different points, count carefully when you judge longevity. If your result took a full week to arrive and started fading at week twelve, you had roughly eleven weeks of effect, not twelve. Practices that book a two week follow up are not upselling you. Two weeks is the first honest look at what the dose did, and it is also the starting line for measuring how long it holds.

Only three of the six FDA approved cosmetic neurotoxins state a duration of effect on their label. Botox Cosmetic says approximately 3 to 4 months for glabellar lines. Dysport says the clinical effect may last up to four months. Xeomin says the typical duration of effect of each treatment is up to 12 to 16 weeks and adds that it may vary in individual patients. The other three say nothing at all about how long the result lasts.

That silence matters when you are quoted a duration at a consultation. Daxxify is frequently sold on longevity, and the published phase 3 trials support a longer result: severity of none or mild was maintained for a median of 24.0 weeks in one study and 23.9 weeks in the other, with severity not returning to baseline for a median of 27.7 and 26.0 weeks. Those numbers come from the peer reviewed SAKURA 1 and SAKURA 2 publication, not from the label, which reports only that subjects were followed for at least 24 weeks and that the product is given no more frequently than every three months.

The distinction is not a technicality. A published trial median describes what happened to a group of enrolled subjects under a fixed dose and protocol. A label duration statement is a claim the FDA reviewed and approved as suitable for general use. When a practice quotes you six months, ask which of the two they are citing.

Units are also not transferable across the products in this table. Each label says so explicitly, and it is why Dysport uses 50 Units where Botox uses 20 for the same five injection sites. Comparing a per unit price across brands is meaningless, as is comparing a unit count.

Duration varies by area, but only four cosmetic areas have any label backing at all, and only the frown lines have a published duration figure. Botox Cosmetic is approved for glabellar lines, lateral canthal lines at 24 Units, forehead lines at 20 Units given together with 20 Units in the glabella, and platysma bands. Xeomin is approved across the same three upper face regions. Every other area you will see advertised is an off label use of an approved drug, which is legal and common but means no regulator has reviewed a duration claim for it.

So when a practice tells you masseter Botox lasts longer and a lip flip lasts less, they are reporting clinical experience rather than label data. The mechanical reasoning is sound. A large, dense muscle receiving a proportionally larger dose tends to hold a result longer than a small, constantly moving one. The upper lip works every time you speak, eat, drink and smile, and it is treated with a very small number of units, so the effect there is conventionally described as the shortest of any area.

The same logic explains why the lower face is treated more conservatively in general. Muscles around the mouth are recruited constantly and sit next to structures you do not want weakened, so the dose that would extend duration is also the dose that risks an asymmetric smile.

If you want planning ranges by area, our units chart sets out what is conventionally used where and how long each region is generally expected to hold. Treat those as convention drawn from practice, and treat the table in the previous section as the part a regulator actually reviewed.

If you want a longer result and only one variable can change, dose is the variable with real trial evidence behind it. A double blind dose ranging study in 80 women compared 10, 20, 30 and 40 Units in the glabella and found the relapse rate at four months was 83 percent in the 10 Unit group against 28, 30 and 33 percent in the 40, 30 and 20 Unit groups. Most subjects had benefit for 3 to 4 months, and some held an effect for up to 12 months.

A companion study in 80 men compared 20, 40, 60 and 80 Units and found a dose dependent increase in both the response rate at maximum frown and the duration of effect, concluding that men benefit from starting doses of at least 40 Units in that area. That is twice the label dose, and it is the clearest published explanation of why a man and a woman treated on the same day can report very different longevity.

This is the honest mechanism behind the common complaint that a cheap treatment did not last. An underdosed area is not a defective product. It is a smaller dose producing a shorter effect, exactly as the dose ranging data predicts. It is also why a per unit price without a unit count tells you nothing about value.

Dose is not a lever you pull without limits. Higher doses in the wrong muscle produce heaviness, brow drop and an expression you did not ask for, and no neurotoxin dose can be undone once it is placed. Every one of these labels notes that the antitoxin available through the CDC will not reverse effects already apparent when it is given. The remedy for too much is waiting. That asymmetry is why experienced injectors start conservatively with a new patient and adjust upward at a follow up rather than opening at a high dose to win on longevity.

Expect your first treatment to be the least representative one, and expect your durable number to appear by the second or third cycle. Injectors commonly start a new patient near the low end of a range because underdosing is correctable in two weeks and overdosing is not correctable at all. A first result that faded at ten weeks is frequently a dosing question rather than a fact about your body.

Muscle bulk is a genuine driver and shows up in the label data. In the Botox Cosmetic glabellar studies, investigator rated responder rates at day 30 were 85 percent among 334 women and 59 percent among 71 men at the same 20 Unit dose. The male dose ranging study above resolves that gap by raising the dose, which supports the plain reading: stronger, denser muscle needs more product to reach the same endpoint and to hold it.

Age appears in the label too. Responder rates at day 30 were 83 percent in subjects under 65 and 39 percent in subjects 65 or older, a gap the label repeats for every approved area. Skin quality and the depth of an etched line, not just muscle activity, are part of what changes there.

Now the claim you have certainly been told. Fast metabolism, heavy endurance training and thyroid conditions are widely reported by injectors to shorten duration, and you will find them asserted as fact across the industry. We could not locate a controlled trial establishing any of them, and none of the six product labels mentions metabolism, exercise or thyroid status in connection with how long the effect lasts. Treat them as clinical observation that has not been tested, not as a mechanism you can plan around. What is tested is dose and product choice.

Treatment history cuts the other way and is worth raising. Patients treated consistently often report holding the same result on the same dose or slightly less over time. Needing steadily more product each cycle is the pattern worth flagging to your injector, because it can reflect stretched intervals or persistent underdosing rather than a change in you.

Before you conclude a product failed, establish what you actually received. Ask for the product name, the units placed in each area, and the date. Without those three facts, no one can tell whether your result was short because the dose was small, because the area is a high movement region, or because the product was a poor fit for your goal.

Then ask how the practice handles a short result. A clear answer sounds like a plan: review at two weeks, adjust units in the specific areas where movement returned first, and record the revised dose for next time. A vague answer that jumps straight to a higher priced product without touching the dose is worth a second opinion.

Ask what the next interval should be. Every label in the table above sets a floor of three months between treatments, so a practice offering a top up at six weeks is proposing something outside the labeled dosing for all six products. That is a conversation to have openly with whoever performs your good faith exam, not something to discover afterward.

Finally, treat a rate far below the local norm as a question rather than a bargain. Product sourced outside authorized distribution is documented: in 2024 the FDA alerted the public that unsafe counterfeit versions of Botox had been found in multiple states and administered for cosmetic purposes, that the products appeared to have been purchased from unlicensed sources, and that it was aware of adverse events including hospitalizations. Dilution is set by the practice and appears on no price list. In either case the units being counted may not be the units reaching your muscle. Duration is the symptom patients notice first.